{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:06:36Z","timestamp":1792782396007,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, MD, USA","id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, MD, USA","id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Roche Diagnostics"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (\u2264 40%) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan\u2013Meier event rate 34.5% at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan\u2013Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Risk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials.<\/jats:p>\n                    <jats:p>Clinical trial registration: ClinicalTrials.gov ID number NCT01685840.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1450","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T01:55:31Z","timestamp":1553738131000},"page":"770-778","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Clinical Factors Related to Morbidity and Mortality in High-Risk Heart Failure Patients: The GUIDE-IT Predictive Model and Risk Score"],"prefix":"10.1093","volume":"21","author":[{"given":"Christopher","family":"O'Connor","sequence":"first","affiliation":[{"name":"Inova Heart and Vascular Institute , Fairfax, VA ,","place":["USA"]},{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Mulder","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Coles","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine and Center for Outcomes Research, Yale University School of Medicine New Haven , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada; Division of Cardiology, Department of Medicine, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirkwood F.","family":"Adams","sequence":"additional","affiliation":[{"name":"University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana L.","family":"Pi\u00f1a","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Department of Biostatistics and Bioinformatics, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawton S.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Mark","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Division of Cardiology, Department of Medicine, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Whellan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Leifer","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Division of Cardiology, Department of Medicine, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"2026011721305197800_ejhf1450-bib-0001","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721305197800_ejhf1450-bib-0002","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure model","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"2026011721305197800_ejhf1450-bib-0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/CIRCHEARTFAILURE.111.963462","article-title":"Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model","volume":"5","author":"O'Connor","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCHEARTFAILURE.112.967828","article-title":"Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram","volume":"6","author":"Barlera","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0005","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.949","article-title":"Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization","volume":"20","author":"Lupon","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0006","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.290.19.2581","article-title":"Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model","volume":"290","author":"Lee","year":"2003","journal-title":"JAMA"},{"key":"2026011721305197800_ejhf1450-bib-0007","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ijcard.2013.01.005","article-title":"Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF\/NT-proBNP risk score","volume":"168","author":"Scrutinio","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721305197800_ejhf1450-bib-0008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/heartjnl-2013-303632","article-title":"A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score","volume":"100","author":"Salah","year":"2014","journal-title":"Heart"},{"key":"2026011721305197800_ejhf1450-bib-0009","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ahj.2008.04.030","article-title":"Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"156","author":"O'Connor","year":"2008","journal-title":"Am Heart J"},{"key":"2026011721305197800_ejhf1450-bib-0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/CIRCULATIONAHA.105.170769","article-title":"Standards for statistical models used for public reporting of health outcomes","volume":"113","author":"Krumholz","year":"2006","journal-title":"Circulation"},{"key":"2026011721305197800_ejhf1450-bib-0011","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jchf.2018.02.001","article-title":"Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"6","author":"Canepa","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0012","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2014.05.007","article-title":"Rationale and design of the GUIDE-IT study: guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure","volume":"2","author":"Felker","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0013","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"2026011721305197800_ejhf1450-bib-0014","first-page":"1","article-title":"Evaluation of the performance of survival analysis models: discrimination and calibration measures","volume":"23","author":"D'Agostino","year":"2004","journal-title":"Handbook of Statistics"},{"key":"2026011721305197800_ejhf1450-bib-0015","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ehf2.12278","article-title":"Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides","volume":"5","author":"Sawano","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0016","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jchf.2017.12.014","article-title":"Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF","volume":"6","author":"Savarese","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCHEARTFAILURE.113.000284","article-title":"Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) study","volume":"7","author":"Cleland","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0018","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026011721305197800_ejhf1450-bib-0019","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11897-018-0375-y","article-title":"An appraisal of biomarker-based risk-scoring models in chronic heart failure: which one is best?","volume":"15","author":"Doumouras","year":"2018","journal-title":"Curr Heart Fail Rep"},{"key":"2026011721305197800_ejhf1450-bib-0021","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jchf.2016.05.008","article-title":"Racial and ethnic differences in heart failure readmissions and mortality in a large municipal healthcare system","volume":"4","author":"Durstenfeld","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0022","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026011721305197800_ejhf1450-bib-0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurjhf\/hfs029","article-title":"The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction","volume":"14","author":"O'Connor","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721305197800_ejhf1450-bib-0024","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ejhf.785","article-title":"Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure","volume":"19","author":"Voors","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/21\/6\/770\/66192966\/eurjhf_21_6_770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/21\/6\/770\/66192966\/eurjhf_21_6_770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:31:06Z","timestamp":1768703466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/21\/6\/770\/8408033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,27]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1450","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"2018-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}